CliffBio
small molecule

DELSTRIGO

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Loss of exclusivityNovember 2036latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug detail

Brand nameDELSTRIGO
Active ingredientDORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Strength100MG;300MG;300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Listed patents

PatentExpiresType
10603282November 2036product
10842751November 2036product
8486975August 2032substance, product

More from MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DELSTRIGO patent cliff — loss of exclusivity November 2036 | CliffBio